Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|October 23, 2018
Evonik Launches Advanced Combination Polymer for Enteric Coatings
Author(s)Pharmaceutical Technology Editors
An advanced combination polymer for enteric coatings has been launched by Evonik and will be showcased during AAPS PharmSci 360 in Washington D.C.
Advertisement
Specialty chemicals company Evonik has launched an advanced combination polymer for enteric coatings, Eudragit FL 30 D-55, which leverages the company’s new advanced excipient manufacturing process (AEMP) technology.
The combination polymer is suitable for the compression of coated multiparticulates due to its flexibility that enables plasticizer-free formulations. The company reports that the spray suspension preparation times can be reduced by 70%. Additionally, it has been shown to reduce film thickness, meaning that there is a possibility for increased drug loading with multiparticulates.
"As the first ever excipient based upon our proprietary AEMP technology, Eudragit FL 30 D-55 combines the best features of two well-accepted polymers including Eudragit L 30 D-55, which has been the gold standard for enteric coatings for decades," said Paul Spencer, global head of Oral Drug Delivery Solutions for the Health Care business line of Evonik in a
Visitors to AAPS PharmSci 360, taking place in Washington DC from Nov. 4–7, 2018, can find out more about this product at booth 9K20.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5